2024
Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum
Trelle A, Young C, Vossler H, Benitez J, Cody K, Mendiola J, Swarovski M, Le Guen Y, Feinstein I, Butler R, Channappa D, Romero A, Park J, Shahid‐Besanti M, Corso N, Chau K, Smith A, Skylar‐Scott I, Yutsis M, Fredericks C, Tian L, Younes K, Kerchner G, Deutsch G, Davidzon G, Sha S, Henderson V, Longo F, Greicius M, Wyss‐Coray T, Andreasson K, Poston K, Wagner A, Mormino E, Wilson E. Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum. Alzheimer's & Dementia 2024, 21: e14442. PMID: 39713875, PMCID: PMC11848181, DOI: 10.1002/alz.14442.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseCognitive declinePositron emission tomographyAmyloid-betaTau accumulationAmyloid positivityHippocampal-dependent memoryAlzheimer's disease spectrumAmyloidAmyloid accumulationTau burdenAb accumulationRisk of cognitive declineSensitive to memoryTau positron emission tomographyAlzheimer's Disease Research CenterPredicting cognitive declineAlzheimerTauScalable biomarkersAD continuumCerebral amyloid accumulationCross-sectional associationsCI individualsAccumulation
2023
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease
Cohen S, van Dyck C, Gee M, Doherty T, Kanekiyo M, Dhadda S, Li D, Hersch S, Irizarry M, Kramer L. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease. The Journal Of Prevention Of Alzheimer's Disease 2023, 10: 771-777. PMID: 37874099, DOI: 10.14283/jpad.2023.123.Peer-Reviewed Original ResearchConceptsZarit Burden InterviewPhase 3 trialEarly Alzheimer's diseaseAlzheimer's diseaseQoL-ADPartner burdenMean changeDouble-blind phase 3 trialCerebrospinal fluid evidenceHumanized IgG1 monoclonal antibodyMarkers of amyloidLife-5 DimensionsHealth-related qualityPhase 3 developmentCare partner burdenLess increaseCerebral amyloid accumulationLess declineYears of ageQuality of lifePositron emission tomographyMild cognitive impairmentIgG1 monoclonal antibodyValuable patientsBurden Interview
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply